Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01208194
Other study ID # MGN1703-C02
Secondary ID 2009-017432-40
Status Completed
Phase Phase 2
First received August 27, 2010
Last updated June 19, 2014
Start date June 2010
Est. completion date March 2013

Study information

Verified date June 2014
Source Mologen AG
Contact n/a
Is FDA regulated No
Health authority Germany: Paul-Ehrlich-InstitutAustria: Federal Office for Safety in Health CareUnited Kingdom: Medicines and Healthcare Products Regulatory AgencyFrance: Agence Francaise de Securite Sanitaire des Produits de SanteRussian Federation: Ministry of Healthcare and Social Development of the Russian FederationCzech Republic: State Institute for Drug Control
Study type Interventional

Clinical Trial Summary

This is a phase 2, randomized, double-blind, multi-center clinical study to evaluate efficacy and safety of a maintenance therapy with the immunomodulator MGN1703 compared to placebo control. The study will be conducted in patients with advanced colorectal carcinoma (AJCC Stage IV) with disease control after first-line standard chemotherapy regimens.


Description:

The phase 2 study will be conducted in patients with advanced colorectal carcinoma with disease control after first-line standard chemotherapy regimens with oral or intravenous fluoropyrimidines/leucovorin and irinotecan or oxaliplatin combined with a standard dose of bevacizumab lasted between 4.5 and 6 months, whereas the treatment duration with irinotecan or oxaliplatin should not be less than 3 months. Studies confirmed that completely chemotherapy-free intervals can be applicable in patients with advanced colorectal carcinoma who achieved disease control after initial first-line chemotherapy. Those therapy holidays minimize toxicity and unnecessary treatment load, reduce intensity of treatment, allow patients to stay longer on therapy, prevent therapy discontinuations due to toxicity, preserve the ability to re-administer chemotherapy later, and increase quality of life of the patients. The therapy-free interval represents a possibility to evaluate the efficacy of the study drug, MGN1703.


Recruitment information / eligibility

Status Completed
Enrollment 59
Est. completion date March 2013
Est. primary completion date December 2012
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Male and female subjects older than 18 years of age

- Histologically confirmed colorectal carcinoma

- Radiological confirmation of unresectable advanced colorectal carcinoma (AJCC Stage IV) prior to start of initial first-line therapy

- At least one measurable lesion according to RECIST measured within 2 weeks prior to treatment start in case of partial response or stable disease

- Prior initial first-line therapy included oral or intravenous fluoropyrimidines/leucovorin,irinotecan or oxaliplatin with or without a standard dose of bevacizumab lasted between 4.5 and 6 months and finished (last day of last cycle) within 2 weeks prior to treatment start (treatment duration with irinotecan or oxaliplatin should not be less than 3 months)

- Patients who achieved disease control measured as objective response or disease stabilization after initial first-line therapy

- No curative standard therapy is available for the patient after first-line treatment

- ECOG performance status 0-1

- Adequate organ function, hemoglobin = 9 g/L, white blood cell count (WBC) = 3.0 x 109/L, absolute neutrophil count = 1.5 x 109/L, platelets > 100 x109/L, aspartate and alanine aminotransferase (AST and ALT) = 2.5 x ULN, bilirubin < 1.5 x ULN, blood creatinine = 1.5 X ULN, prothrombin time (PT) and activated thromboplastin time (aPTT) within normal range

- Negative pregnancy test in women with childbearing potential

- Expected adequacy of follow-up

- Signed informed consent form (ICF)

Exclusion Criteria:

- More than one line of systemic chemotherapy for metastatic colorectal carcinoma

- Tumor progression after initial first-line therapy

- Clinically significant concomitant diseases or conditions, which in opinion of the investigator would lead to an unacceptable risk for the subject to participate in the study

- Prior or current other malignancy, except adequately treated superficial bladder cancer, basal or squamous cell carcinoma of the skin or other cancer for which the subject has been disease free for more than 3 years

- Known central nervous system metastases

- Active or uncontrolled infections

- Transfusion-dependent anemia

- History of autoimmune disease or immune deficiency

- Known hypersensitivity to oligonucleotides or excipients of the formulation

- Pregnancy and/or nursing

- Concurrent chronic systemic immune therapy or immunosuppressant medication, including steroid treatment

- Concurrent chemotherapy, hormonal therapy (except hormonal contraception and hormonal replacement therapy for menopausal women), or immunotherapy within the last 2 weeks prior to randomization or during the conduct of the study - Concurrent radiotherapy within the last 6 months prior to randomization or during the conduct of the study

- Known HIV seropositivity or active hepatitis B or C infection

- Planned major surgery during the study

- Participation in another clinical study with other investigational drugs within 30 days prior to the first treatment day

- Vaccination within 3 months prior to the first treatment day

- Any medical, mental, psychological or psychiatric condition which in opinion of the investigator would not permit the subject to complete the study or understand the patient information

- Presence of drug and/or alcohol abuse

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Intervention

Drug:
MGN1703
solution, 60 mg, twice a week, until progression
Placebo
solution, 60 mg, twice a week, until progression

Locations

Country Name City State
Austria Klinik für Innere Medizin I, Abteilung für Klinische Onkologie, Medizinische Universität Wien Wien
Czech Republic Oncology Clinic, Faculty Hospital Olomouc Olomouc
France Service de Cancérologie Digestive, Institut de Cancérologie Gustave Roussy Villejuif
Germany Onkologischer Schwerpunkt am Oskar-Helene-Heim Berlin
Germany Klinik für Innere Medizin IV, Onkologie/ Hämatologie/ Hämostaseologie, Universitätsklinikum Halle (Saale) Halle
Germany Kath. Marienkrankenhaus GmbH, Allgemeine Onkologie Hamburg
Germany Schwerpunktpraxis für Hämatologie und Onkologie Magdeburg
Germany Klinik für Innere Medizin, Klinik für Hämatologie, Onkologie, Immunologie, Universitätsklinikum Giessen und Marburg GmbH Marburg
Germany Medizinische Klinik, Abteilung für Onkologie, Hämatologie Immunologie, Rheumatologie und Pulmologie Universität Tübingen, Immuntherapie, Station 65 Med. Klinik Abt. II Tübingen
Russian Federation Non-state health care institution "Central Clinical Hospital No. 2 named after N.A. Semashko OAO "RZHD" Moscow
Russian Federation State Institution "Russian Scientific Oncology Center named after N.N. Blokhin RAMN" Moscow
United Kingdom Mount Vernon Cancer Centre Northwood Middlesex

Sponsors (1)

Lead Sponsor Collaborator
Mologen AG

Countries where clinical trial is conducted

Austria,  Czech Republic,  France,  Germany,  Russian Federation,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Evaluation of median progression-free survival (PFS) in both treatment groups Measured on accrual time 3 years No
Secondary Assessment of PFS rate Measured at landmarks 12, 18 and 24 weeks after treatment start, and afterwards every 6 weeks until treatment stop No
Secondary Evaluation of median overall survival (OS) Measured on accrual time 3 years No
Secondary Assessment of OS proportion in both groups Measured at landmarks 12, 18 and 24 weeks after treatment start, and afterwards every 6 weeks until treatment stop No
Secondary Evaluation of overall response rate (ORR) Measured on accrual time 3 years No
Secondary Evaluation of duration of response (complete response, partial response, stable disease) as time from initial determination of response to progressive disease measured by RECIST Measured on accrual time 3 years No
Secondary Assessment of the dynamic of clinical and laboratory parameters An average time: participants are followed until progress No
Secondary Evaluation of immunologic response to MGN1703 An average time: participants are followed until progress No
Secondary Assessment of quality of life (QOL) An average time: participants are followed until progress No
Secondary Assessment of the safety profile of MGN1703 An average time: participants are followed until progress No
See also
  Status Clinical Trial Phase
Recruiting NCT04582981 - Fruquintinib and Raltitrexed Versus Fruquintinib Monotherapy in Advanced Colorectal Cancer Phase 2
Active, not recruiting NCT04164069 - Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without Bevacizumab Phase 1
Terminated NCT05648006 - First-line Maintenance of OH2 Injection for Advanced Colorectal Cancer Phase 2
Active, not recruiting NCT04771715 - Regorafenib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Patients With Advanced Colorectal Cancer
Recruiting NCT05733000 - CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors Phase 2
Active, not recruiting NCT02983578 - Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal Cancer Phase 2
Recruiting NCT05967533 - The Immune Effects of Fermented Wheat Germ Nutritional Supplementation in Patients With Advanced Solid Tumor Cancers Being Treated With Standard of Care Checkpoint Inhibitors Phase 1
Recruiting NCT05894694 - Survival Benefit of Compound Kushen Injection in the Treatment of Advanced Colorectal Cancer Phase 4
Recruiting NCT04705818 - Combining Epigenetic And Immune Therapy to Beat Cancer. Phase 2
Not yet recruiting NCT05883683 - Molecular Study and Precision Medicine for Colorectal Cancer
Recruiting NCT05759923 - First-in-human Phase I Study to Evaluate Safety, Tolerability and Antineoplastic Activity of OATD-02 in Patients With Selected Advanced and/or Metastatic Solid Tumours Phase 1
Completed NCT01277406 - 4SC-201 (Resminostat) in Advanced Colorectal Carcinoma Phase 1/Phase 2
Completed NCT04645797 - A Dose Escalation Study of APR003 in Patients With Advanced Colorectal Cancer (CRC) With Malignant Liver Lesions Phase 1
Recruiting NCT05406206 - Hepatic Arterial Infusion Chemotherapy With Fruquintinib for Colorectal Cancer Liver Metastases As Third-line Therapy Phase 2
Active, not recruiting NCT04109924 - TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Cancer, the TABAsCO Study Phase 2
Recruiting NCT04704661 - Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Patients With Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial Phase 1
Recruiting NCT05969860 - At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer Phase 2
Recruiting NCT05200442 - A Study of VS-6766 and Cetuximab in Patients With Advanced Colorectal Cancer Phase 1/Phase 2
Completed NCT00499850 - Phase I FOLFOX Combination Phase 1
Active, not recruiting NCT04535401 - Testing the Addition of an Anticancer Drug, BAY 1895344, to the Usual Chemotherapy With FOLFIRI in Advanced or Metastatic Cancers of the Stomach and Intestines Phase 1